Clinical Trial: Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction.

Brief Summary: The multi-center, double-blind, placebo-controlled, randomized, group-comparison study was designated to assess the long-term safety and efficacy of the antiplatelet drug cilostazol in preventing the recurrence of cerebral infarction in patients who had suffered a cerebral infarction 1 to 6 months prior to entering the trial.

Detailed Summary:
Sponsor: Otsuka Pharmaceutical Co., Ltd.

Current Primary Outcome: Recurrence of cerebral infarction [ Time Frame: any time ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Cerebral infarction or myocardial infarction, Cerebral infarction, intracranial hemorrhage, or TIA, Cerebral infarction, intracranial hemorrhage, myocardial infarction, or vascular death, All vascular events, vascular death, and Death from any cause [ Time Frame: any time ]

Original Secondary Outcome: Same as current

Information By: Otsuka Pharmaceutical Co., Ltd.

Dates:
Date Received: October 2, 2008
Date Started: April 1992
Date Completion:
Last Updated: January 8, 2009
Last Verified: January 2009